TITLE

Review: Atenolol may be ineffective for reducing cardiovascular morbidity or all-cause mortality in primary hypertension

PUB. DATE
May 2005
SOURCE
ACP Journal Club;May/Jun2005, Vol. 142 Issue 3, p59
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
This article cites a medical study which states that atenolol may be ineffective for reducing cardiovascular morbidity or all-cause mortality in primary hypertension. Randomized controlled trials (RCTs) were done that assessed the effect of atenolol (as the sole first-line drug in one of the treatment groups) on cardiovascular morbidity or mortality in patients with primary hypertension. Studies were also required to have predefined criteria for myocardial infarction, stroke, and cardiovascular death.
ACCESSION #
17116514

 

Related Articles

  • Review: β-blockers are less effective than other antihypertensive drugs for reducing risk for stroke in primary hypertension.  // ACP Journal Club;May/Jun2006, Vol. 144 Issue 3, p67 

    The article discusses a study which determines whether β-blockers are more effective than placebo or other antihypertensive drugs for reducing stroke, myocardial infarction and all-cause mortality in patients with primary hypertension. β-blockers were compared with placebo or no treatment...

  • Sudden death: ACE inhibitors and beta-blockers. Landray, M. J. // Basic Research in Cardiology;Nov2000 Supplement 1, Vol. 95, pI37 

    Sudden death is extremely common in patients suffering from cardiovascular diseases. At least one third of those with hypertension and probably about half of those who survive a myocardial infarction or suffer from cardiac failure who die in a clinical trial, die suddenly. Beta-blockers reduce...

  • atenolol.  // Royal Society of Medicine: Medicines;2002, p91 

    This article presents information on beta-blocker atenolol. The drug can be used as an antihypertensive for raised blood pressure, as an anti-angina treatment to relieve symptoms and to improve exercise tolerance, to regularize heartbeat and after anti-arrhythmic myocardial infarction. Atenolol...

  • Betim.  // Royal Society of Medicine: Medicines;2002, p113 

    The article presents information on Betim, a proprietary, prescription-only preparation drug of the beta-blocker timolol maleate. This drug can used as an antihypertensive for high blood pressure, as an anti-angina treatment to relieve symptoms and improve exercise tolerance and to treat...

  • Losartan: A Review of its Use in Stroke Risk Reduction in Patients with Hypertension and Left Ventricular Hypertrophy. Moen, Marit D.; Wagstaff, Antona J. // Drugs;2005, Vol. 65 Issue 18, p2657 

    Losartan (Cozaar®) is an angiotensin AT1 receptor antagonist. It is approved in numerous countries for the treatment of hypertension and has been approved in the UK, the US and several European countries for stroke risk reduction in patients with hypertension and left ventricular hypertrophy...

  • Routine use of beta-blockers following myocardial infarction: a note of dissent. Greenbaum, R. A. // Journal of the Royal Society of Medicine;Jul1987, Vol. 80 Issue 7, p402 

    The author comments on the use of beta-blockers for the treatment of myocardial infarction (MI). Among the strategies tried to treat myocardial infarction include predischarge exercise test and the use of beta-blockers. In the Beta-blocker Heart Attack Trial, it revealed that propanolol is an...

  • Indendent Nurse: Hypertension - Beta-blockers linked to higher stroke risk.  // GP: General Practitioner;10/28/2005, p81 

    This article informs that according to researchers at the Umea University Hospital, who conducted a meta analysis of 13 randomised controlled trials involving 100,000 patients, stroke risk is 16 per cent higher with beta blockers compared with other drugs. The research also found beta-blockers...

  • Benefits and risks associated with β-blocker prophylaxis in noncardiac surgery. White, C. Michael; Talati, Ripple; Phung, Olivia J.; Baker, William L.; Reinhart, Kurt; Sedrakyan, Art; Kluger, Jeffrey; Coleman, Craig I. // American Journal of Health-System Pharmacy;4/1/2010, Vol. 67 Issue 7, p523 

    The article focuses on the benefits and risks factors associated with the use of B-blocker prophylaxis in noncardiac surgeries (NCSs). It discusses the clinical trials which evaluated the effect of perioperative B-blockers on myocardial infarction (MI), stroke, and hypotension. It says that...

  • Increase in blood glucose concentration during antihypertensive treatment as a predictor of myocardial infarction: population based cohort study. Dunder, Kristina; Lind, Lars; Zethelius, Bjorn; Berglund, Lars; Lithell, Hans // BMJ: British Medical Journal (International Edition);3/29/2003, Vol. 326 Issue 7391, p681 

    Abstract Objective: To investigate the impact of an increase in blood glucose on the risk of developing myocardial infarction, with particular emphasis on people taking antihypertensive drugs. Design: Prospective population based cohort study. Setting: Uppsala, Sweden. Participants: 1860 men who...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics